<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940742</url>
  </required_header>
  <id_info>
    <org_study_id>17102</org_study_id>
    <secondary_id>I8F-MC-GPGQ</secondary_id>
    <nct_id>NCT03940742</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide in Participants With Impaired Liver Function</brief_title>
  <official_title>A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how fast tirzepatide gets into the blood stream and
      how long it takes the body to remove it in participants with impaired liver function compared
      to healthy participants. The study will last about two months and will include five visits to
      the study center.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">August 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide</measure>
    <time_frame>Predose through 336 hours postdose</time_frame>
    <description>PK: AUC(0-∞) of Tirzepatide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide</measure>
    <time_frame>Predose through 336 hours postdose</time_frame>
    <description>PK: Cmax of Tirzepatide</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Tirzepatide Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered subcutaneously (SC) to participants with normal hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Mild</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered SC to participants with mild hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Moderate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered SC to participants with moderate hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Severe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered SC to participants with severe hepatic impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Tirzepatide Control</arm_group_label>
    <arm_group_label>Tirzepatide Mild</arm_group_label>
    <arm_group_label>Tirzepatide Moderate</arm_group_label>
    <arm_group_label>Tirzepatide Severe</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Participants:

          -  Women of childbearing potential are excluded from the study.

          -  Women not of childbearing potential may participate and include those who are
             infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or
             tubal ligation), congenital anomaly such as mullerian agenesis; or postmenopausal

          -  Are between the body mass index (BMI) of 19.0 and 40.0 kilograms per meter squared
             (kg/m²), inclusive, at screening

        Healthy Participants:

        - Healthy males or females as determined by medical history, physical examination, and
        other screening procedures, with normal liver function

        Participants with Impaired Liver Function:

          -  Males or females with chronic mild, moderate and severe liver impairment, assessed by
             Child-Pugh scoring

          -  Have type 2 diabetes mellitus (T2DM) controlled with diet or exercise alone or on
             stable doses of metformin for at least 8 weeks

          -  Have a hemoglobin A1c (HbA1c) ≥6.0% and ≤11.0% at screening

        Exclusion Criteria:

        All Participants:

          -  Have known allergies to tirzepatide or related compounds

          -  Have a personal or family history of medullary thyroid carcinoma or have multiple
             endocrine neoplasia syndrome type 2

          -  Have a history or presence of pancreatitis (history of chronic pancreatitis or
             idiopathic acute pancreatitis), elevation in serum amylase or lipase or GI disorder
             (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which
             impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the
             exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1)
             analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors

        Participants with Impaired Liver Function:

          -  Have hemoglobin &lt;8.5 grams per deciliter (g/dL)

          -  Have kidney function that is significantly impaired at screening

          -  Have taken any glucose-lowering medications other than metformin, including insulin,
             in the past 3 months before screening

          -  Have brain function impaired significantly due to liver condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-550-9990</phone>
    </contact>
    <investigator>
      <last_name>Joel M Neutel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>865-305-9100 ext 7</phone>
    </contact>
    <investigator>
      <last_name>William B. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/adult-type-2-diabetes/GPGQ#?postal=</url>
    <description>A Study of Tirzepatide in Participants With Impaired Liver Function</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LY3298176</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

